PIK3CA and breast cancer: A recent meta-analysis, including eight studies with 2670 patients, showed that the PIK3CA mutation is a favorable predictive factor of objective response rate (ORR) (odds ratio: 1.98) and PFS (hazard ratio (HR) = 0.65) in HR+ BC treated by a PI3K inhibitor [49].